Clinical trial
Repurposing Montelukast for the Attenuation and Prophylaxis of Severe COVID-19 Symptoms: The COvid-19 Symptom MOntelukast (COSMO) Trial
NCT04389411 is registered in ClinicalTrials.gov with McGill University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Repurposing Montelukast for the Attenuation and Prophylaxis of Severe COVID-19 Symptoms: The COvid-19 Symptom MOntelukast (COSMO) Trial
- Lead sponsor
- McGill University
- Phase
- Phase 2/3
- Overall status
- Unknown status
- Start date
- November 1, 2022
- Completion date
- February 28, 2025
- Enrollment
- 250 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.